Personally, it is one of my favourite Creative Reviews to date, so please do give it a read.
We love hearing your feedback so please do let us know what you think. 😊
90TEN will retain its brand and service offering, bringing its insight-led behavioral science model Feel-Think-Do™ to a broad spectrum of Envision Pharma Group’s communications solutions. This partnership will enrich Envision Pharma Group’s global reach in medical affairs, which include its flagship technology, iEnvision®, together with strategic publications planning and delivery, medical strategy and communications, market access, and creative and digital solutions. In adding 90TEN’s strengths in behavioral science, creativity, and insight-driven communications, this acquisition will deliver an enhanced service offering to the Group’s global client base.
“We’re delighted to welcome an award-winning healthcare communications consultancy into the Envision Pharma Group family,” said David Thompson, CEO, Envision Pharma Group. “90TEN will add its expertise across new verticals for the group – in corporate communications and public relations, while extending Envision’s current footprint in patient engagement and medical communications with its behavioral science methodology. This move bolsters our industry-leading scientific communications capabilities, and enables us to strengthen our offering to clients across the product life cycle.”
“Today marks an exciting milestone in the evolution of 90TEN,” said Paul Tanner, Chairman, 90TEN. “Envision Pharma Group will provide global support to accelerate our plans to extend into more markets and reach more audiences. Both companies share the same values, which is reflected in the similarities between our passionate, ambitious, and collaborative teams who are dedicated to improving patient outcomes.”
Carole North, CEO, 90TEN added, “We’ve always said, if we partnered with another company it would have to be one that was the right strategic and cultural fit for 90TEN, celebrating everything that is 90TEN and the people who make it so successful. Envision Pharma Group embodies all of this and will allow us to retain our individuality, culture, and entrepreneurial spirit as we continue to deliver life-changing communications.”
90TEN will be managed from its London headquarters by the existing management team, including co-founders Paul Tanner and Carole North, and Managing Directors Peter Impey and Alison Doughty.
Based in London, 90TEN employs around 70 members of staff, and works with over half of the top 20 pharma companies in the world serving clients across Europe and North America. The acquisition of 90TEN will bring the total number of Envision Pharma Group employees to around 800 across 14 offices and four continents.
90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and communications. 90TEN provides PR, medical communications, and patient advocacy services that use behavioral science methodologies to maximize brand and health outcomes. 90TEN is one of the leading healthcare communications consultancies in Europe. In 2019, 90TEN was named Communications Consultancy of the Year at the Communiqué Awards; European Agency of the Year at the PR Week Global Awards; Specialist Consultancy of the Year at the PR Week UK Awards; and Support Agency of the Year at the PMEA Awards. To find out more, visit www.90ten.co.uk.
Founded in 2001, Envision Pharma Group is a global, innovative technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies. Envision is a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision®) that have applicability across many areas of medical affairs and related functional responsibility. Envision Pharma Group provides services and technology solutions to more than 90 companies, including all of the top 20 pharmaceutical companies.
Envision has 14 offices: six in the United Kingdom – Bishop’s Stortford, Glasgow, Horsham, London (Battersea and Hammersmith), and Wilmslow; one in Serbia – Subotica; one in Hungary – Szeged; four in the United States – Fairfield and Glastonbury, CT, Philadelphia, PA, Warren, NJ; and two in the Asia-Pacific region – Tokyo and Sydney. The company employs around 800 team members, including over 250 highly qualified and experienced in-house medical writers, and 190 technology solutions team members who provide software development and customer support. To find out more, visit www.envisionpharmagroup.com.
The acquisition was supported by Envision’s equity partners – Ardian, one of the largest European headquartered private investment funds, and the specialist investor in European healthcare, GHO Capital.
Marsha Caplin
Global Head of Marketing
Envision Pharma Group
Email: marsha.caplin@envisionpharmagroup.com
Tel: +44 (0)7557 083549
Peter Impey
Managing Director, Communications Division
90TEN
Email: peter.impey@90ten.co.uk
Tel: +44 (0)7921 879688
“Given that the pharmaceutical industry is powered by experimentation and discovery, healthcare should be leading the way when it comes to innovative communications,” said Edel McCaffrey, an HCA Executive Committee member and one of the driving forces behind Cannes or Canned?“That isn’t always the case, so we set up this initiative to find out two things: what is holding back our creativity, and what can we do to set it free?”
Cannes or Canned? brought together UK and internationally based senior communicators from seven pharmaceutical companies. With input and inspiration from innovators in industries including banking, fashion retail, artificial intelligence and toy marketing, they identified four key forces stifling innovation in communications and five recommendations for overcoming them.
The five key recommendations discussed in the report are:
“As healthcare communicators we help to put the pharmaceutical industry’s life-changing discoveries into patients’ hands, but healthcare is changing fast and unless we think creatively and embrace innovation, we risk losing our voice,” said Peter Impey, Managing Director of 90TEN’s Communications division. “These recommendations are a recipe for making our communications braver, bolder and more creative, and I’m very excited to see where they take the healthcare communications sector.”
Healthcare communicators are invited to join the movement to open up creativity and innovation in healthcare communications:
Further press information contact:
Mike Dixon at the HCA
email: mikedixon@the-hca.org
call: +44 (0)7799 865794
About Cannes or Canned?
Cannes or Canned? is an HCA initiative in partnership with 90TEN. It brought together UK and internationally based senior communicators and included representatives from seven pharmaceutical companies:
Paul Tanner, chairman and co-founder of 90TEN said: “The outcomes of the improving access to SIRT campaign is testament to the success of 90TEN’s behaviour change methodology in driving measurable improvements in health outcomes. With a 14-year heritage of delivering behaviour change across PR, medical education and medication adherence programmes, 90TEN is proud to be recognised for its life changing work.”
Bowel cancer that spreads to the liver is one of the biggest cancer killers in the UK and innovative solutions are needed that can offer extended survival for patients. SIR-Spheres microspheres is a radiotherapy procedure that delivers millions of microscopic radioactive beads directly into tumours in the liver and can significantly extend life. With awareness of the procedure low, there was a clear need to educate patients and healthcare professionals about this life-extending treatment and to help them understand where and how they can access it.
By developing an integrated product campaign that mobilised clinical advocates, supported patients to tell their story and harnessed the power of the media, Sirtex, makers of SIR-Spheres, saw a dramatic increase in awareness among patient and clinicians and referrals to specialist centres increased significantly.
Commenting on Improving access to SIRT, the Communiqué judges said: “The clear, but simple, strategy we saw here ticked all the criteria boxes. Straight-forward, with SMART objectives and focused tactics, they delivered impressive outcomes and clear benefits for patients. We liked the great transition between awareness, objectives and results in this truly integrated campaign. This could serve as best practice for what you can accomplish on a tight budget.”
